Retacrit®
ACTIVE PRINCIPLE:
Epoetin Zeta
INDICATION:
Anemia secondary to oncological processes
end-stage renal failure
DATE:
27/02/2008
STATUS:
Authorized
ACTIVE PRINCIPLE:
Epoetin Zeta
INDICATION:
Anemia secondary to oncological processes
end-stage renal failure
DATE:
27/02/2008
STATUS:
Authorized